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1. Introduction 
Venous and arterial thromboembolic disorders (e.g. pulmonary embolism, deep vein 
thrombosis) are quite serious problem all over the world. Vessels occluding blood clot can be formed 
by coagulation of blood, which causes deep vein thrombosis and/or pulmonar embolism in most cases. 
Untreated thromboembolism lead to cardiac or cerebral infarction or in more severe case to death. For 
about 10% of the hospital mortality these disorders are responsible.  
Anticoagulants are used for the prevention and treatment of these diseases, which inhibit the 
undisered coagulation processes. In the last decades many anthitrombotic drugs were developed for 
inhibition of enzymes in the coagulation pathways. 
Heparin has been present on the market for decades until today and is one of the most often 
applied anticoagulants, even though it has a number of limitation including the risk of life-threatening 
heparin-induced thrombocytopaenia. Heparin is a sulfated glycosaminoglycan (GAGs) consisting of 
1→4 linked hexuronic acids (D-glucuronic and L-iduronic acids in a ratio of 1:9) and glucosamine 
with varying degrees of sulfation. This negatively charged linear polysaccharide is found inside cells 
and in the extracellular matrix. It is an indirect inhibitor of trombin through binding to antithrombin 
(AT, a serine protease inhibitor) which is a regulator protein in the coagulation cascade. Presence of 
unique pentasaccharide unit (DEFGH, 1) within a polysaccharide is nessecery for the anticoagulant 
effect. Its synthetic analogue (2, fondaparinux sodium) has been used under the name Arixtra
®
 in the 
medicine since 2001. Some analogues of fondaparinux were prepared in the last decades. One of the 
most promising molecule is idraparinux (3) which is a non-glycoseaminoglycan analogue of 
fondaparinux and it is a more easier obtainable derivative. Its main advantage is the excellent 
anticoagulation effect (Scheme 1.).  
 
 
Scheme 1. Structure and anticoagulant activity of the active pentasaccharide domain 
(1) of heparin and its synthetic derivatives (2, 3, 44 and 45) 
 
Our group has been dealing with the synthesis of bioisosteric sulfonic acid analogues of 
idraparinux in order to obtain novel selective factor Xa inhibitors. Advantage of these molecules is the 
higher resistance against sulfatase and hydrolase enzyms, therefore they are able to exert their 
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anticogulant effect at a constant level. Two pentasaccharide sulfonic acids (44 and 45) and the 
reference compound idraparinux (3) have been prepared by now. Evaluation of the inhibitory activities 
of pentasaccharides (3, 44 and 45) towards the blood-coagulation proteinase factor-Xa revealed that 
the disulfonate analogue 44 displayed higher activity than idraparinux, however, introduction of the 
third sulfonic-acid moiety (45) resulted in a notable decrease in anti-Xa activity. It revealed that the 
position and number of the replaced sulfate groups are very important. To gain deeper insight into the 
structure–activity relationship of the anticoagulant action of the sulfonic acid derivatives we decided to 
prepare a series of heparinoid pentasaccharides by systematic replacement of the primary sulfate esters 
with a sodium sulfonatomethyl moiety. 
The aim of my PhD project was the preparation of this series of pentasaccharide sulfonic acids 
(6-10) in protected form (Scheme 2.). Moreover, we also aimed at preparing compounds 45 in a 
sufficient amount for detailed STD NMR studies of its interactions with antithrombin. 
 
 
Scheme 2. Structure of the designed pentasaccharide di- and monsulfonic acids in protected form  
2. Methods 
In the course of synthetic work, macro, semimicro and micro methods of modern preparative 
organic chemsitry were applied. The purity of the substances, the ratio of products were controlled and 
the reactions were monitored by thin-layer chromatography. Purification of the crude products and 
separation of the isomers were carried out either by crystallization, column chromatography, gel 
chromatography or ion exchange chromatography. The characterisation and the elucidation of the 
compounds were carried out by elemental analysis, melting point- and optical rotation determination, 
and by one and two-dimensional (1H-1H-COSY, 13C-1H-HSQC, TOCSY, ROESY) NMR 
spectroscopy and MALDI/ESI-TOF mass spectrometric methods, respectively. 
3. The new scientific results of the dissertation 
3.1. Elaboration of modular synthetic route 
We elaborated a modular synthetic pathway to obtain the new pentasaccharides 6-10 containing 
6-sulfonic acid moieties (Scheme 3.). Based on the retrosynthetic analysis the target molecules can be 
disconnected to two DE dissacharide donor and four FGH trisaccharide acceptor blocks, which can be 
built up from only eight monosaccharide units (51-58). 
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Scheme 3. Retrosynthetic analysis of the series of pentasaccharide 6-sulfonic acids 
 
Thus we synthesized all of the monosaccharide units in sufficient amounts for the preparation 
of the targeted pentasaccharide series (Scheme 4.). 
 
 
Scheme 4. Monosaccharide building blocks 
3.2. Synthesis of monosaccharides containing a sulfonic acid 
3.2.1. Two synthetic routes for unit H 
For large scale synthesis of monosaccharide sulfonic acids (53, 55 and 57), an effective method 
was developed including nucleophilic substitution of the corresponding glucoside-6-O-triflate with 
lithiated ethyl methanesulfonate. This reaction was excellent for the synthesis of O-glucoside 
derivative (Scheme 5.) and we produced unit H (57) in almost 10 grams. The synthesis of the target 
molecule 57 by using ioidine as a leaving group (78) was also attempted. Although the synthesis was 
sucsessful, the efficacy of this route was low.  
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Scheme 5. Synthesis of unit H containing a sulfonic acid moiety 
3.2.2. Synthesis of unit F by using two temporary protecting groups 
For the synthesis of glycosyl donor F containing a sulfonatomethyl group (84), we used 
-thioglucoside derivative 83 as the starting molecule (Scheme 6.). However the product (84) was not 
formed. Because of an undesired 1→6 thio-migration was able took place, due to an intramolecular 
substitution reaction. We elaborated two methodes to avoid the intramolecular side-reaction of the 
anomeric thio group. In one case, we locked the 
4
C1 conformation of the sugar ring to prevent the 
conformational change. Alternatively the corresponding -thioglycoside (55), was used for synthesis 
of the end-product. 
 
 
Scheme 6. 1→6 Thio-migration through a sulfonium ion intermedier 
 
Starting from -thioglucoside derivative 91 we could synthesize the unit F with high yield 
using 2-NAP as the temporary protecting group. Two temporary protecting groups were tried in the 
reaction route (Scheme 7.).  
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Scheme 7. Formation of unit F containing a sulfonic acid moiety from 
-thioglucoside by using either Np- or PMP-acetal protection 
 
3.2.2. Synthesis of unit D 
The synthesis of monosaccharide sulfonic acid unit D was carried out also from the starting -
thioglucoside derivative (91). We prepared the target molecule (53) with an excellent yield and nearly 
in 10 grams (Scheme 8.). 
 
 
Scheme 8. Formation of unit D containing 6-sulfonatomethyl group 
 
Building blocks (51, 52, 54, 56, 58), which do not contain the sulfonatomethyl group, were 
prepared according to the literature methods.  
 
3.3. Large scale synthesis of DE building blocks, optimization of the glycosylation reaction 
The synthesis of DE disaccharide containing sulfonic acid (107) was completed in a large scale 
in a chemo- and stereoselective way (Scheme 9.). A wide variety of glycosyl donors (102, 105, 106) 
and promoters were tested in the glycosylation of units D and E.  
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Scheme 9. Glycosylation reactions for synthesis of disaccharide donor DE 
containing a sulfonatomethyl group 
 
Formation of an aglycon transfer side product (108 , was observed when glycosyl bromide 
(106) and -thioglycoside (105) were used as the donors (Scheme 10.). This competitive side reaction 
could be avoided with the use of -thioglycoside at a low temperature and a short reaction time. 
 
 
Scheme 10. Mechanism of glycosyl transfer side reaction during synthesis of disaccharide donor DE 
 
Based on our previous experiments, the suitable DE disaccharide was prepared in appropriate 
amount for the pentasaccharides which do not contain sulfonatomethyl moiety on the unit D. 
 
 
 
 
 
 
 Donor Promoter (ekv.) T (°C) Time 
Yield 
(39) 
by-products 
1 -SPh (105) NIS (1.1) – AgOTf (0.2) −75 - −15 1.5h 11 108 9%) 
2 -Br (106) AgOTf (1.5) −30 1.5h 21 108 %) 
3 -SEt (102) NIS (1.5) – TfOH (0.1) −75 - −50 3h 31 
degradation 
products 
4 -SEt (102) NIS (1.5) – TMSOTf (0.2) −75 - −55 2h 44 109 (8%) 
5 -SEt (102) NIS (1.1) – AgOTf (0.2) −75 - −55 45min 66  
6 -SEt (102) NIS (1.1) – AgOTf (0.2) −75 - −65 45min 89  
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3.4. Synthesis of GH building blocks  
 
Scheme 11. Preparation of the GH buliding blocks  
 
We carried out the formation of two diaccharide acceptors GH (111, 112) by the glycosylation 
of units H (57, 58) with the L-idose derivative (51), and subsequent formation of the L-iduronic acid 
moiety at a disaccharide level (Scheme 11.). 
3.5. Synthesis of FGH trisaccharide acceptors  
 
Scheme 12. Preparation of the FGH building blocks 
 
FGH trisaccharide acceptor precursors (117-120) were prepared by condensation of GH 
disaccharide acceptors (115, 116) and F monosaccharide donors (55, 56) respectively. In all cases the 
promoter was TfOH-NIS system, and except for synthesis of 118, the coupling reactions took place 
with good yields. We could increase the yield of derivative 118 to 73% by using AgOTf-NIS as the 
promoter. FGH trisaccharide acceptors were achieved by removal of the 2-naphtylmethyl group from 
the position 4 of unit F (Scheme 12.).  
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3.6. Synthesis of new pentasaccharides containing sulfonic acid moieties  
We synthesized the target pentasaccharides (46-50) and the pentasaccharide trisulfonic acids 
(125) in protected form by the glycosylation of the FGH trisaccharide acceptors (121-124) with DE 
disaccharide donors (107, 110) respectively. All glycosylation reactions took place in a stereoselective 
way and we obtained the products in good yields (Scheme 13).  
 
 
Scheme 13. Synthesis of the new pentasaccharide derivatives 
3.7. Elaboration of a new synthetic route: synthesis of a L-idose-containing pentasaccharide  
Furthermore, we carried out the synthesis of a sixth pentasaccharide derivative (126) as well, which is 
the non-oxidised analouge of compound 50 containing the D-glucuronic and L-iduronic acids in their 
precursor forms (Scheme 14). Therefore it can be suitable for the investigation of simultaneous 
oxidation of both units at a pentasaccharide level. For the preparation of pentasaccharide (126), the 6-
hydroxyl group of the GH disaccharide was protected with terc-butyl-diphenylsilyl ether group instead 
of oxidation. Then the GH disaccharide acceptor (127) was glycosylated with F monosaccharide donor 
(56). After the of the 2-naphtylmethy protecting group, the FGH trisaccharide acceptor was 
glycosylated with the DE disaccharide donor containing a sulfonatomethyl moiety (107).  
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Scheme 14. Preparation of pentasaccharide 126 containing non-oxidised 
precursors of the uronic acid units  
3.8. New synthesis of pentasaccharide trisulfonic acid 45 and antithrombin-carbohydrate 
interaction studies 
Second part of my work was the transformation of the pentasaccharide trisulfonic acid (125) 
into the trisulfonic acid end-product (45) in eight steps, in 100 mg scale (Scheme 15).  
 
 
Scheme 15. Modification of pentasaccharide 125 to the corresponding target molecule (45) 
 
This compound was utilized by our co-workers for antithrombin-carbohydrate interaction studies. 
Three-dimensional structures of the free and AT-binded forms of the trisulfonate analogue were 
10 
 
determined by using different NMR spectroscopic data and dynamics simulations (Scheme 16.). A 
significant difference in the structure and the conformational flexibility of the idraparinux and its 
analogue was observed. There is also a notable difference in the 3D structures of the free and bound 
form of the trisulfonic analogue, revealing that a change in the conformation is required for the 
activation of antithrombin.  
 
Scheme 16. Molecular model of free (green) and AT-bound (blue) forms of 
pentasaccharide trisulfonic acid (45) 
 
3.9. Synthesis of the new idraparinux analogue  
As a contiunation of my PhD work, I plan to convert the protected pentasaccharides into the 
corresponding idraparinux-analogue end-products. We have already started the modification of 
pentasaccharide 48 which contains sulfonic acid moieties on units D and F (Scheme 17). 
 
 
Scheme 17. Modification of the protected pentasaccharide disulfonic acid (48) to the 
corresponding end-product 
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